1. The clinical effect of novel HMG CoA reductase inhibitor, BAY w 6228, on hyperlipidemia in diabetic patients;Amano;Japanese Pharmacology and Therapeutics,1996
2. Arakawa K A comparative and long term trial of a new HMG CoA reductase inhibitor, BAY w 6228 150 mug/day and 300 mug/day in patients with hyperlipidemia Japanese Pharmacology and Therapeutics 1996 147 70
3. Long-term trial of a new HMG-CoA reductase inhibitor, BAY w 6228 (cerivastatin) in patients with hyperlipidemia;Arakawa;Japanese Pharmacology and Therapeutics,1997
4. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial;Balletshofer;Experimental and Clinical Endocrinology & Diabetes,2005
5. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?;Battula;Metabolism: Clinical and Experimental,2000